Tiragolumab (anti-TIGIT)

目录号：A2028         批次号: A202801

打印

Tiragolumab (anti-TIGIT) (RG6058, MTIG7192A) 是一种人源化 IgG1/kappa 单克隆抗体，可与 TIGIT 结合以防止其与其配体 PVR (CD155) 相互作用。

抗体信息

CAS号 1918185-84-8
推荐同型对照 Human IgG1, κ
来源 CHO cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.
除菌 0.2 μM filtered
纯度 99.33%
蛋白浓度 4.72 mg/ml
内毒素 <1 EU/mg

Tiragolumab (anti-TIGIT)在文献中得到引用

Combined dendritic cell and anti-TIGIT immunotherapy potentiates adaptive NK cells against HIV-1 [ EMBO Mol Med, 2025, 10.1038/s44321-025-00255-x] PubMed: 40473838
Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy [ NPJ Precis Oncol, 2025, 9(1):142] PubMed: 40374899
Novel insights into immune checkpoints in HIV/SHIV infection: from SHIVSF162P3-infected elite controllers to therapeutic strategy [ J Virol, 2025, 99(8):e0078525] PubMed: 40637373
Dual targeting of CD155/TIGIT and PD-L1/PD-1 immune checkpoints potentiates NK cell-mediated cytotoxicity in medulloblastoma [ Neurooncol Adv, 2025, 7(1):vdaf099] PubMed: 40703802
Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer [ Cancer Cell, 2024, 42(12):2045-2063.e10] PubMed: 39658541
Inhibition of Cbl-b restores effector functions of human intratumoral NK cells [ J Immunother Cancer, 2024, 12(11)e009860] PubMed: 39551607
The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling [ Cell Commun Signal, 2024, 22(1):35] PubMed: 38216949
Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer [ bioRxiv, 2024, 2024.03.19.585657] PubMed: 38562799
Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies [ J Immunother Cancer, 2023, 11(12)e007502] PubMed: 38081778

禁止用于人体及治疗！